SK Biopharmaceuticals Co., Ltd.
326030
Classifica tra le azioni
#3727
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Prezzo delle azioni
$56.51
Capitalizzazione di mercato
$4.43B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-25.24%
Paese
KR
Scambia SK Biopharmaceuticals Co., Ltd. (326030)
Categoria
Healthcare
Storico del prezzo dell'azione per SK Biopharmaceuticals Co., Ltd. (326030)
Prezzo di chiusura più alto: $51.70 il 2026-10-01
Prezzo di chiusura più basso: $157.85 il 2020-07-01
Prezzo di chiusura più basso: $157.85 il 2020-07-01
Storico del prezzo dell'azione di SK Biopharmaceuticals Co., Ltd. dal 2020 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -22.47% |
| 2025 | 24.61% |
| 2024 | 2.56% |
| 2023 | 25.24% |
| 2022 | -33.05% |
| 2021 | -47.19% |
| 2020 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $533.96 | 25.21% |
US
|
|
| $232.80 | 767.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $882.27 | 8.36% |
NL
|
|
| $290.30 | 1.99% |
BE
|
